Learn how an expert manages resistance to 2 prior TKIs in adults with CP-CML

Find out why TKI resistance is a “critical action window” when considering your next treatment

Learn from expert Javier Pinilla-Ibarz, MD, PhD*

Head of Lymphoma Section at the Moffitt Cancer Center

*Disclaimer: This is a promotional non-CME program intended only for healthcare professionals involved in the treatment of CP-CML. Javier Pinilla-Ibarz, MD, PhD is a paid consultant of Takeda Pharmaceuticals USA, Inc. (Takeda Oncology). This video is intended for informational purposes only and is not a substitute for your clinical knowledge or professional judgment. The views and opinions expressed in this video are those of the presenter and Takeda Oncology and do not necessarily reflect the opinions of the Lymphoma Section at the Moffitt Cancer Center.

For many patients, ICLUSIG may be the right next step as soon as they fail their second TKI

99% of participants in the OPTIC trial were heavily pretreated with TKIs1  

98% were resistant to their prior therapy1

Category 2A, preferred NCCN recommendation.

OPTIC is an ongoing, dose-optimization trial evaluating 3 starting doses (45 mg/day, 30 mg/day, and 15 mg/day) of ICLUSIG in 282 adult patients with CP-CML whose disease was considered to be resistant or resistant/intolerant to at least 2 prior TKI therapies or who have the T315I mutation. Patients were randomized 1:1:1 to 3 cohorts, 45 mg/day, 30 mg/day, or 15 mg/day. Dose reductions were applied to the 45 mg/day and 30 mg/day cohorts upon achievement of ≤1% BCR::ABL1IS.

AP-CML= accelerated phase chronic myeloid leukemia; BP-CML=blast phase chronic myeloid leukemia; CP-CML= chronic phase chronic myeloid leukemia; NCCN=National Comprehensive Cancer Network® (NCCN®); TKIs=tyrosine kinase inhibitors.